Additional indications for interferon therapy: basal cell carcinoma, carcinoid, and chronic active hepatitis.
Spiegel
R J
RJ
Clinical Research Division, Schering Corporation, Kenilworth, NJ 07033.
D002276:Carcinoid Tumor / Q000628:therapy*; D002280:Basal Cell Carcinoma / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007414:Intestinal Neoplasms / Q000628:therapy; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000628:therapy
D007370:Interferon Type I; D011994:Recombinant Proteins